These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 15077081)
1. Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes. Collet JP; Montalescot G; Golmard JL; Tanguy ML; Ankri A; Choussat R; Beygui F; Drobinski G; Vignolles N; Thomas D Am Heart J; 2004 Apr; 147(4):655-61. PubMed ID: 15077081 [TBL] [Abstract][Full Text] [Related]
2. The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients. Lee DS; Bhatt DL; Moliterno DJ; Peacock WF; Ellis SG; Topol EJ J Invasive Cardiol; 2004 Feb; 16(2):46-51. PubMed ID: 14760188 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. White HD; Kleiman NS; Mahaffey KW; Lokhnygina Y; Pieper KS; Chiswell K; Cohen M; Harrington RA; Chew DP; Petersen JL; Berdan LG; Aylward PE; Nessel CC; Ferguson JJ; Califf RM Am Heart J; 2006 Dec; 152(6):1042-50. PubMed ID: 17161049 [TBL] [Abstract][Full Text] [Related]
4. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Montalescot G; Collet JP; Tanguy ML; Ankri A; Payot L; Dumaine R; Choussat R; Beygui F; Gallois V; Thomas D Circulation; 2004 Jul; 110(4):392-8. PubMed ID: 15249498 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4). Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ; Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. Mehta SR; Granger CB; Eikelboom JW; Bassand JP; Wallentin L; Faxon DP; Peters RJ; Budaj A; Afzal R; Chrolavicius S; Fox KA; Yusuf S J Am Coll Cardiol; 2007 Oct; 50(18):1742-51. PubMed ID: 17964037 [TBL] [Abstract][Full Text] [Related]
7. Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial. Mahaffey KW; Ferguson JJ Am Heart J; 2005 Apr; 149(4 Suppl):S81-90. PubMed ID: 16124952 [TBL] [Abstract][Full Text] [Related]
8. Enoxaparin and percutaneous coronary intervention: a Canadian perspective. Fitchett D; Welsh R; Langer A; Goodman S Can J Cardiol; 2005 May; 21(6):501-7. PubMed ID: 15917879 [TBL] [Abstract][Full Text] [Related]
9. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. Cannon CP; Weintraub WS; Demopoulos LA; Vicari R; Frey MJ; Lakkis N; Neumann FJ; Robertson DH; DeLucca PT; DiBattiste PM; Gibson CM; Braunwald E; N Engl J Med; 2001 Jun; 344(25):1879-87. PubMed ID: 11419424 [TBL] [Abstract][Full Text] [Related]
10. Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative). Alexander D; Mann N; Ou FS; Peterson ED; Ohman EM; Gibler WB; Roe MT Am J Cardiol; 2008 Nov; 102(10):1335-40. PubMed ID: 18993151 [TBL] [Abstract][Full Text] [Related]
11. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Lewis BS; Mehta SR; Fox KA; Halon DA; Zhao F; Peters RJ; Keltai M; Budaj A; Yusuf S; Am Heart J; 2005 Dec; 150(6):1177-84. PubMed ID: 16338255 [TBL] [Abstract][Full Text] [Related]
12. Primary PCI for ST-segment elevation myocardial infarction in a patient treated with subcutaneous enoxaparin utilizing point-of-care Enox test. Veerappan B; Latif F; Patibandla S; Hennebry T; Ghani M; Saucedo J; Schechter E; Sadanandan S J Invasive Cardiol; 2003 May; 15(5):4p following A16. PubMed ID: 12784820 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial. Jolly SS; Faxon DP; Fox KA; Afzal R; Boden WE; Widimsky P; Steg PG; Valentin V; Budaj A; Granger CB; Joyner CD; Chrolavicius S; Yusuf S; Mehta SR J Am Coll Cardiol; 2009 Jul; 54(5):468-76. PubMed ID: 19628124 [TBL] [Abstract][Full Text] [Related]
15. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. ; Yusuf S; Mehta SR; Chrolavicius S; Afzal R; Pogue J; Granger CB; Budaj A; Peters RJ; Bassand JP; Wallentin L; Joyner C; Fox KA N Engl J Med; 2006 Apr; 354(14):1464-76. PubMed ID: 16537663 [TBL] [Abstract][Full Text] [Related]
16. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. Montalescot G; White HD; Gallo R; Cohen M; Steg PG; Aylward PE; Bode C; Chiariello M; King SB; Harrington RA; Desmet WJ; Macaya C; Steinhubl SR; N Engl J Med; 2006 Sep; 355(10):1006-17. PubMed ID: 16957147 [TBL] [Abstract][Full Text] [Related]
17. Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association guidelines (CRUSADE). Alexander D; Ou FS; Roe MT; Pollack CV; Ohman EM; Cannon CP; Gibler WB; Fintel DJ; Peterson ED; Brown DL; Am Heart J; 2008 Sep; 156(3):606-12. PubMed ID: 18760147 [TBL] [Abstract][Full Text] [Related]
18. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. Mehta SR; Boden WE; Eikelboom JW; Flather M; Steg PG; Avezum A; Afzal R; Piegas LS; Faxon DP; Widimsky P; Budaj A; Chrolavicius S; Rupprecht HJ; Jolly S; Granger CB; Fox KA; Bassand JP; Yusuf S; Circulation; 2008 Nov; 118(20):2038-46. PubMed ID: 18955665 [TBL] [Abstract][Full Text] [Related]
19. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial. Sabatine MS; Morrow DA; Giugliano RP; Murphy SA; Demopoulos LA; DiBattiste PM; Weintraub WS; McCabe CH; Antman EM; Cannon CP; Braunwald E Circulation; 2004 Feb; 109(7):874-80. PubMed ID: 14757697 [TBL] [Abstract][Full Text] [Related]
20. Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST-elevation acute coronary syndromes: observations from the OPUS-TIMI 16 trial. Cantor WJ; Goodman SG; Cannon CP; Murphy SA; Charlesworth A; Braunwauld E; Langer A Am Heart J; 2005 Feb; 149(2):275-83. PubMed ID: 15846265 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]